| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1000 - 0.1000 |
| 52 Week Range | 0.0310 - 1.4800 |
| Volume | 49 |
| Avg. Volume | 4,377 |
| Market Cap | 5.372M |
| Beta (3Y Monthly) | -1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0720 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office. The endocannabinoid system and other physiological systems can potentially mitigate the effects of organophosphate and carbamate toxicity when treated with medicaments affecting these systems in a time and dose-dependent format. Nexien’s unique process for treating symptoms incorporates a composition comprising tetrahydrocannabinol and cannabidiol formulated for administration by an oral, nasal, buccal, sublingual, parenteral, or any combination thereof.
DENVER, CO / ACCESSWIRE / March 28, 2019 / Nexien BioPharma, Inc. ("Nexien" or the "Company") (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development, ...
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that its patent application No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” has been accepted by the Israeli Patent Office. This application relates to pharmaceutical formulation compositions and their method of use in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier to treat or prevent disorders caused by exposure to an organophosphate or carbamate acetylcholinesterase inhibitor.
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced encouraging results of clinical observations of patient groups consisting of patients suffering from non-dystrophic myotonia and myotonic dystrophies (DM) type 1 and 2, indicating that specific cannabinoid formulations are supportive in relief of myotonia and DM symptoms. Nexien intends to proceed with related clinical studies in accordance with U.S. Food and Drug Administration (FDA) protocols, commencing with the filing of a Pre-IND meeting request.
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced executive and business updates. Dr. Joseph F. Aceto, JD, Ph.D. has been appointed as the Company’s Interim Director of Translational Research. In this role, Dr. Aceto will oversee the ongoing evolution of Nexien’s research programs, to develop, license, and commercialize pharmaceuticals utilizing cannabinoids as the Active Pharmaceutical Ingredients (APIs).
Since May 9, 2018, when Alain Bankier sent out the last shareholder letter, we have been very busy at Nexien BioPharma (“Nexien” or the “Company”) building the foundation for a bio-pharmaceutical company. This joint letter from Alain, the former CEO and now Executive Board Chair, and Alex Wasyl, our current CEO and Board member, will help highlight some of the recent events at Nexien. One of the more obvious changes has been the name change to Nexien BioPharma.
DENVER, Colo., Nov. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”).
DENVER, CO / ACCESSWIRE / November 26, 2018 / Nexien BioPharma, Inc. (OTCQB: NXEN) (''Nexien'' or the ''Company'') is a US-based pharmaceutical company focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. CEO, Alex Wasyl, joined Stock Day's Everett Jolly for the first time to discuss the recent acquisition of CRX Bio-Holdings by Nexien BioPharma, and the Company's future in the pharmaceutical industry. Jolly began the interview by asking Wasyl to provide some background information about the Company.
DENVER, CO / ACCESSWIRE / November 6, 2018 / Nexien BioPharma Inc. (NXEN) ("Nexien" or the "Company") announced that it was initiating an investigation into the use of cannabinoid-based formulations for the treatment of patients suffering from Myotonic Dystrophy (DM) and Myotonia. Munich-based Dr. Benedikt Schoser, who joined Nexien as a scientific advisor in July, and myotonic dystrophy patient organizations, recently shared two questionnaires. One was in Germany and the other in the United States with both DM type 1 and DM type 2 patients.
DENVER, CO / ACCESSWIRE / October 30, 2018 / Nexien BioPharma, Inc. (NXEN) (''Nexien'' or the ''Company'') announced today that it has acquired Princeton, New Jersey based CRx Bio Holdings LLC (''CRx''). CRx is engaged in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. Nexien and CRx both share a common vision of developing cannabinoid based and U.S. Food and Drug Administration ("FDA")approved therapeutics to treat specific medical conditions.